Can Lurbinectedin Allergies Be Treated?
Lurbinectedin (brand name Zepzelca), used for metastatic small cell lung cancer, can trigger hypersensitivity reactions or allergies, often during infusion. These range from mild skin rashes to severe anaphylaxis, occurring in up to 10% of patients in clinical trials.[1][2] Treatment follows standard protocols for chemotherapy-related allergies: immediate discontinuation of the infusion, administration of antihistamines (e.g., diphenhydramine), corticosteroids (e.g., dexamethasone), and epinephrine for anaphylaxis. Patients typically stabilize quickly with these interventions.[2][3]
How Are Hypersensitivity Reactions Managed During Infusion?
Reactions usually start within minutes of infusion. Protocol requires:
- Stopping the drug instantly.
- Giving IV antihistamines and steroids premedication-style, even if not pre-administered.
- Monitoring vital signs; oxygen or bronchodilators if breathing issues arise.
In trials, most patients (over 80%) resumed treatment after reaction resolution with premeds.[2] No specific antidote exists, but supportive care resolves symptoms in nearly all cases.[3]
Can You Continue Lurbinectedin After an Allergic Reaction?
Desensitization is possible for mild-to-moderate reactions. This involves gradual re-exposure under supervision, starting at 1/1000th dose and ramping up over hours. Success rates exceed 90% in oncology settings for similar drugs.[3][4] Severe anaphylaxis often rules out retrying lurbinectedin, shifting to alternatives. Guidelines from NCCN recommend risk-benefit assessment by oncologists.[1]
What Premedications Prevent Lurbinectedin Allergies?
FDA labeling mandates premedication before each dose: dexamethasone 10 mg IV 30 minutes prior, plus optional antihistamines or H2 blockers like ranitidine. This cuts reaction risk by 50-70%.[2] Patients with prior reactions get intensified regimens, such as added montelukast.[3]
What Alternatives Exist if Allergies Persist?
Switch to topotecan (IV or oral), irinotecan, or clinical trials for relapsed SCLC. Immunotherapy combos like atezolizumab may suit some profiles but aren't direct swaps.[1] No biosimilars yet; Jazz Pharmaceuticals holds exclusivity.[5]
Are Lurbinectedin Allergies Common or Predictable?
Seen in 3-10% of patients, higher with faster infusions. No clear predictors like IgE levels, but history of platinum allergies raises risk. Cross-reactivity with trabectedin (similar mechanism) occurs in 20-30%.[2][4]
Sources:
[1] NCCN Small Cell Lung Cancer Guidelines
[2] FDA Zepzelca Prescribing Information
[3] J Clin Oncol: Lurbinectedin Hypersensitivity Management
[4] Ann Oncol: Desensitization Protocols
[5] DrugPatentWatch.com: Zepzelca Patents and Exclusivity